Showing 1 - 6 results of 6 for search 'V. M. Tolmachev', query time: 0.03s Refine Results
  1. 1
    Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins

    Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins by O. D. Bragina, V. I. Chernov, S. M. Deyev, V. M. Tolmachev

    Published 2022-10-01
    Get full text
    Article
  2. 2
    Possibilities of predicting the HER2 / neu status in a primary tumor in breast cancer patients using <sup>99m</sup>Tc-DARPinG3

    Possibilities of predicting the HER2 / neu status in a primary tumor in breast cancer patients using <sup>99m</sup>Tc-DARPinG3 by O. D. Bragina, L. A. Tashireva, V. I. Chernov, S. M. Deyev, V. M. Tolmachev

    Published 2023-01-01
    Get full text
    Article
  3. 3
    Comparative Analysis of the Clinical Use of 99mTechnetium-Labeled Recombinant Target Molecules in Different Dosages for the Radionuclide Diagnosis of Her2-Positive Breast Cancer

    Comparative Analysis of the Clinical Use of 99mTechnetium-Labeled Recombinant Target Molecules in Different Dosages for the Radionuclide Diagnosis of Her2-Positive Breast Cancer by O. D. Bragina, V. I. Chernov, E. Yu. Garbukov, R. V. Zelchan, A. A. Medvedeva, V. M. Tolmachev

    Published 2021-06-01
    Get full text
    Article
  4. 4
    Possibilities of radionuclide visualization of HER2/neu-positive breast cancer using a radiopharmaceutical based on recombinant targeting molecules DARPin9_29

    Possibilities of radionuclide visualization of HER2/neu-positive breast cancer using a radiopharmaceutical based on recombinant targeting molecules DARPin9_29 by O. D. Bragina, V. I. Chernov, A. A. Medvedeva, R. V. Zelchan, M. S. Larkina, S. M. Deyev, V. M. Tolmachev

    Published 2020-08-01
    Get full text
    Article
  5. 5
    Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use

    Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use by O. D. Bragina, V. I. Chernov, E. Yu. Garbukov, A. V. Doroshenko, A. G. Vorobyeva, A. M. Orlova, V. M. Tolmachev

    Published 2021-04-01
    Get full text
    Article
  6. 6
    EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT)

    EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT) by O. D. Bragina, V. I. Chernov, R. V. Zelchan, A. A. Medvedeva, I. G. Frolova, E. A. Dudnikova, V. E. Goldberg, V. M. Tolmachev

    Published 2021-10-01
    Get full text
    Article

Search Tools: